Christelle Haziza leads the Clinical Science group for Philip Morris International R&D, in Neuchâtel, Switzerland. She focuses her research efforts on harm reduction strategy in the context of smoking. She is accountable for the scientific strategy of PMI clinical assessment programs, conducted with smokers who have switched to the portfolio of reduced-risk products developed within the company, to demonstrate a significantly reduced risk of smoking-related diseases compared with continued smoking of cigarettes. Her experience extends from over a decade of expertise in clinical study design and data reporting, executing complex clinical studies under Good Clinical Practice, to conducting basic research, translational research, and bioanalytical knowledge. She has broad scientific knowledge in cardiovascular and pulmonary diseases, and tobacco research, acquired during her career in both industry and academic environments. Christelle has published numerous articles in international peer-reviewed scientific journals and holds a Ph.D. in Life Sciences.